All In Biotech

Drug Trial Radar · NCT01582321

Investigation of the Influence of Gender on Cardiovascular Function

Investigation of the Influence of Gender on Cardiovascular Function and Inflammation

Last checked: Nov 19, 2026Latest source record: Jun 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Planned (sponsor's estimate)

Start

Mar 2012

Primary completion

Dec 2016

Study completion Jan 2017

Sponsor

Lead sponsor
Queen Mary University of LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Inflammation is a key initiating and damaging factor in many illnesses including infection, arthritis and cancer but also of particular relevance to this study in diseases of the heart and blood vessels (i.e. cardiovascular disease). Much evidence now exists demonstrating that male sex increases ones risk of cardiovascular disease. More recent evidence demonstrates that inflammatory responses in females appear to dampened in comparison to age matched males. Since inflammation is thought to be a key initiating phenomenon in many cardiovascular disease states the investigators will examine the differences in acute inflammatory responses between the sexes in healthy volunteers and the impact this has on the function of blood vessels.

Conditions

  • Cardiovascular Function

Interventions

  • Typhoid vaccineBiological

    The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution

  • CantharidinDrug

    0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison change in blister fluid total and differential leukocyte numbers (Part 1)Time frame: 24, 72 h
  2. Flow-mediated dilatation (Part 2)Time frame: 0, 24, 48 h

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • William Harvey Heart Centre, Barts & The London Medical School

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.